Want to see IN:INDSWFTLAB full AI Analyst Report?

Ind-Swift Laboratories Ltd. (INDSWFTLAB) Price & Analysis

0 Followers

INDSWFTLAB Stock Chart & Stats

₹227.00

₹12.42(5.46%)

At close: Jul 27 4:00 PM EDT

₹227.00

₹12.42(5.46%)

Day’s Range― - ―

52-Week Range₹87.00 - ₹248.00

Previous CloseN/A

Volume478.31K

Average Volume (3M)7.30K

Market Cap

₹19.55B

Enterprise Value₹3.97K

Total Cash (Recent Filing)₹4.72B

Total Debt (Recent Filing)₹205.01M

Price to Earnings (P/E)42.6

Beta0.87

Next Earnings

Aug 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)5.26

Shares Outstanding86,961,555

10 Day Avg. Volume7,859

30 Day Avg. Volume7,299

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)0.79

Price to Sales (P/S)1.71

P/FCF Ratio-10.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthSharp reduction in leverage plus steadily rising equity materially increases financial flexibility. Lower debt service improves the firm's ability to fund operations, absorb shocks, or pursue strategic investments over the coming months without immediate refinancing risks.

Multi-year Revenue GrowthSustained top-line expansion through 2024 demonstrates prior market traction and scalable commercial execution. This multi-year revenue gain indicates underlying product demand and customer acceptance that could support recovery if operational execution stabilizes.

Proven Cash-generation HistoryThe company has historically converted profits into cash, showing the business model can generate free cash under stable conditions. That track record suggests cash recovery is feasible if margins or revenue trends normalize, supporting longer-term resilience.

Bears Say

Weak Recent Cash GenerationThree consecutive years of negative free cash flow and recent negative operating cash flow create persistent liquidity pressure. This limits reinvestment capacity, increases reliance on external financing, and elevates execution and solvency risk over the next several months.

Revenue And Margin DeteriorationSignificant top-line declines and compressed gross profit weaken margin sustainability and reduce economies of scale. Continued revenue erosion impairs cash flow recovery, forces margin-focused restructuring, and raises the bar for durable earnings improvement.

Earnings Volatility And Cash MismatchVolatile reported earnings coupled with weak profit-to-cash conversion undermines earnings quality and forecasting reliability. This complicates capital allocation, debt servicing and investor confidence, increasing execution risk until cash conversion stabilizes.

Ind-Swift Laboratories Ltd. News

Ind-Swift Labs Revises EGM Notice on Preferential Issue for Expansion

An announcement from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) is now available. Ind-Swift Laboratories Ltd. has issued a...

7d ago

Ind-Swift Laboratories to Hold Extraordinary General Meeting via Video Conference on August 5

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has provided an announcement. Ind-Swift Laboratories Ltd. has informed shareholders that it...

23d ago

Ind-Swift Laboratories Seeks Shareholder Nod for Major Leadership Restructuring via Postal Ballot

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) just unveiled an announcement. Ind-Swift Laboratories Ltd. has launched a postal ballot...

4M ago

Ind-Swift Labs Retains ₹19.66 Crore as 6.5 Million Warrants Lapse

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has issued an announcement. Ind-Swift Laboratories has announced that 6.5 million fully...

5M ago

Ind-Swift Labs Files CARE Monitoring Report on Rs 314.6 Crore Preferential Issue

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has shared an announcement. Ind-Swift Laboratories Ltd. has disclosed that CARE Ratings...

6M ago

Ind-Swift Laboratories Closes Trading Window Ahead of Q3 FY2025 Results

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) just unveiled an update. Ind-Swift Laboratories Ltd. has announced the closure of...

7M ago

Ind-Swift Laboratories Completes Intra-Promoter Transmission of 232,057 Shares

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has issued an update. Ind-Swift Laboratories Ltd. has informed the stock exchanges...

8M ago

Ind-Swift Laboratories Secures Trading Approval for New Equity Shares Post-Amalgamation

An announcement from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) is now available. Ind-Swift Laboratories Ltd. has received trading...

8M ago

Ind-Swift Laboratories Announces 30th AGM and Annual Report Availability

An update from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) is now available. Ind-Swift Laboratories Ltd. has announced the...

11M ago

Ind-Swift Laboratories Announces Major Share Allotment Amid Amalgamation

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) just unveiled an update. Ind-Swift Laboratories Ltd. has announced the allotment of...

11M ago

INDSWFTLAB FAQ

What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?

Ind-Swift Laboratories Ltd. lowest stock price was ₹87.00 and its highest was ₹248.00 in the past 12 months.

What is Ind-Swift Laboratories Ltd.’s market cap?

Ind-Swift Laboratories Ltd.’s market cap is ₹19.55B.

When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?

Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 5 days.

How were Ind-Swift Laboratories Ltd.’s earnings last quarter?

Ind-Swift Laboratories Ltd. released its earnings results on May 28, 2026. The company reported ₹1.81 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Ind-Swift Laboratories Ltd. overvalued?

According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ind-Swift Laboratories Ltd. pay dividends?

Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here

What is Ind-Swift Laboratories Ltd.’s EPS estimate?

Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ind-Swift Laboratories Ltd. have?

Ind-Swift Laboratories Ltd. has 86,961,555 shares outstanding.

What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?

Ind-Swift Laboratories Ltd. reported an EPS of ₹1.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:INDSWFTLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ind-Swift Laboratories Ltd.

Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.